Researchers structurally analyzed adenine nucleotide control and neurodegenerative diseases in ClC-3 exchangers.
Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer
Treatment with the investigational bispecific antibody ubamatamab (REGN4018) alone or in combination with the PD-1 inhibitor cemiplimab (Libtayo) appeared to be safe and demonstrated activity